Clinical Trial Update: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

View source ↗

Summary

Expanded Access Protocol update for talimogene laherparepvec in unresected stage IIIB to IV M1c melanoma indicates the protocol is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)

Snippet

Sponsor: Amgen | Conditions: Unresected Stage IIIb to IVM1c Melanoma | Status: NO_LONGER_AVAILABLE